Molecules 2013, 18(1), 140-153; doi:10.3390/molecules18010140
Article

Inhibitory Evaluation of Sulfonamide Chalcones on β-Secretase and Acylcholinesterase

Jae Eun Kang 1,† , Jung Keun Cho 1,† , Marcus J. Curtis-Long 2 , Hyung Won Ryu 1 , Jin Hyo Kim 3 , Hye Jin Kim 1 , Heung Joo Yuk 1 , Dae Wook Kim 1  and Ki Hun Park 1,* email
1 Division of Applied Life Science (BK21 Program), IALS, Gyeongsang National University, Jinju 660-701, Korea 2 Graduate Program in Biochemistry and Biophysics, Brandeis University, 415 South Street, Waltham, MA 02453, USA 3 Chemical Safety Division, National Academy of Agricultural Sciences, RDA, Suwon 441-701, Korea † These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 19 November 2012; in revised form: 16 December 2012 / Accepted: 18 December 2012 / Published: 21 December 2012
PDF Full-text Download PDF Full-Text [308 KB, uploaded 21 December 2012 11:03 CET]
Abstract: The action of β-secretase (BACE1) is strongly correlated with the onset of Alzheimer’s disease (AD). Aminochalcone derivatives were examined for their ability to inhibit BACE1. Parent aminochalcones showed two digit micromolar IC50s against BACE1. Potency was enhanced 10-fold or more by introducing benzenesulfonyl derivatives to the amino group: 1 (IC50 = 48.2 μM) versus 4a (IC50 = 1.44 μM) and 2 (IC50 = 17.7 μM) versus 5a (IC50 = 0.21 μM). The activity was significantly influenced by position and number of hydroxyl groups on the chalcone B-ring: 3,4-dihydroxy 5a (IC50 = 0.21 μM) > 4-hydroxy 4a (IC50 = 1.44 μM) > 2,4-dihydroxy 6 (IC50 = 3.60 μM) > 2,5-dihydroxy 7 (IC50 = 16.87 μM) > des hydroxy 4b (IC50 = 168.7 μM). Lineweaver-Burk and Dixon plots and their secondary replots indicate that compound 5a was a mixed inhibitor with reversible and time-dependent behavior. Potent BACE1 inhibitors 4a,c,f, 5a–c showed moderate inhibition against two other enzymes implicated in AD pathogenesis, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50s ranging between 56.1 ~ 95.8 μM and 19.5 ~ 79.0 μM, respectively.
Keywords: sulfonamide chalcone; Alzheimer’s disease (AD); β-secretase; acetylcholinesterase (AChE); butyrylcholinesterase (BChE); mixed inhibition

Supplementary Files

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Kang, J.E.; Cho, J.K.; Curtis-Long, M.J.; Ryu, H.W.; Kim, J.H.; Kim, H.J.; Yuk, H.J.; Kim, D.W.; Park, K.H. Inhibitory Evaluation of Sulfonamide Chalcones on β-Secretase and Acylcholinesterase. Molecules 2013, 18, 140-153.

AMA Style

Kang JE, Cho JK, Curtis-Long MJ, Ryu HW, Kim JH, Kim HJ, Yuk HJ, Kim DW, Park KH. Inhibitory Evaluation of Sulfonamide Chalcones on β-Secretase and Acylcholinesterase. Molecules. 2013; 18(1):140-153.

Chicago/Turabian Style

Kang, Jae E.; Cho, Jung K.; Curtis-Long, Marcus J.; Ryu, Hyung W.; Kim, Jin H.; Kim, Hye J.; Yuk, Heung J.; Kim, Dae W.; Park, Ki H. 2013. "Inhibitory Evaluation of Sulfonamide Chalcones on β-Secretase and Acylcholinesterase." Molecules 18, no. 1: 140-153.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert